Cargando…
DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials
BACKGROUND AND OBJECTIVES: Clinical trials of genotype-targeted treatments in Duchenne muscular dystrophy (DMD) traditionally compare treated patients with untreated patients with the same DMD genotype class. This avoids confounding of drug efficacy by genotype effects but also shrinks the pool of e...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103111/ https://www.ncbi.nlm.nih.gov/pubmed/36725339 http://dx.doi.org/10.1212/WNL.0000000000201626 |
_version_ | 1785025814851485696 |
---|---|
author | Muntoni, Francesco Signorovitch, James Sajeev, Gautam Lane, Henry Jenkins, Madeline Dieye, Ibrahima Ward, Susan J. McDonald, Craig Goemans, Nathalie Niks, Erik H. Wong, Brenda Servais, Laurent Straub, Volker Guglieri, Michela de Groot, Imelda J.M. Chesshyre, Mary Tian, Cuixia Manzur, Adnan Y. Mercuri, Eugenio Aartsma-Rus, Annemieke |
author_facet | Muntoni, Francesco Signorovitch, James Sajeev, Gautam Lane, Henry Jenkins, Madeline Dieye, Ibrahima Ward, Susan J. McDonald, Craig Goemans, Nathalie Niks, Erik H. Wong, Brenda Servais, Laurent Straub, Volker Guglieri, Michela de Groot, Imelda J.M. Chesshyre, Mary Tian, Cuixia Manzur, Adnan Y. Mercuri, Eugenio Aartsma-Rus, Annemieke |
author_sort | Muntoni, Francesco |
collection | PubMed |
description | BACKGROUND AND OBJECTIVES: Clinical trials of genotype-targeted treatments in Duchenne muscular dystrophy (DMD) traditionally compare treated patients with untreated patients with the same DMD genotype class. This avoids confounding of drug efficacy by genotype effects but also shrinks the pool of eligible controls, increasing challenges for trial enrollment in this already rare disease. To evaluate the suitability of genotypically unmatched controls in DMD, we quantified effects of genotype class on 1-year changes in motor function endpoints used in clinical trials. METHODS: More than 1,600 patient-years of follow-up (>700 patients) were studied from 6 real-world/natural history data sources (UZ Leuven, PRO-DMD-01 shared by CureDuchenne, iMDEX, North Star UK, Cincinnati Children's Hospital Medical Center, and the DMD Italian Group), with genotypes classified as amenable to skipping exons 44, 45, 51, or 53, or other skippable, nonsense, and other mutations. Associations between genotype class and 1-year changes in North Star Ambulatory Assessment total score (ΔNSAA) and in 10-m walk/run velocity (Δ10MWR) were studied in each data source with and without adjustment for baseline prognostic factors. RESULTS: The studied genotype classes accounted for approximately 2% of variation in ΔNSAA outcomes after 12 months, whereas other prognostic factors explained >30% of variation in large data sources. Based on a meta-analysis across all data sources, pooled effect estimates for the studied skip-amenable mutation classes were all small in magnitude (<2 units in ΔNSAA total score in 1-year follow up), smaller than clinically important differences in NSAA, and were precisely estimated with standard errors <1 unit after adjusting for nongenotypic prognostic factors. DISCUSSION: These findings suggest the viability of trial designs incorporating genotypically mixed or unmatched controls for up to 12 months in duration for motor function outcomes, which would ease recruitment challenges and reduce numbers of patients assigned to placebos. Such trial designs, including multigenotype platform trials and hybrid designs, should ensure baseline balance between treatment and control groups for the most important prognostic factors, while accounting for small remaining genotype effects quantified in this study. |
format | Online Article Text |
id | pubmed-10103111 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-101031112023-04-15 DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials Muntoni, Francesco Signorovitch, James Sajeev, Gautam Lane, Henry Jenkins, Madeline Dieye, Ibrahima Ward, Susan J. McDonald, Craig Goemans, Nathalie Niks, Erik H. Wong, Brenda Servais, Laurent Straub, Volker Guglieri, Michela de Groot, Imelda J.M. Chesshyre, Mary Tian, Cuixia Manzur, Adnan Y. Mercuri, Eugenio Aartsma-Rus, Annemieke Neurology Research Article BACKGROUND AND OBJECTIVES: Clinical trials of genotype-targeted treatments in Duchenne muscular dystrophy (DMD) traditionally compare treated patients with untreated patients with the same DMD genotype class. This avoids confounding of drug efficacy by genotype effects but also shrinks the pool of eligible controls, increasing challenges for trial enrollment in this already rare disease. To evaluate the suitability of genotypically unmatched controls in DMD, we quantified effects of genotype class on 1-year changes in motor function endpoints used in clinical trials. METHODS: More than 1,600 patient-years of follow-up (>700 patients) were studied from 6 real-world/natural history data sources (UZ Leuven, PRO-DMD-01 shared by CureDuchenne, iMDEX, North Star UK, Cincinnati Children's Hospital Medical Center, and the DMD Italian Group), with genotypes classified as amenable to skipping exons 44, 45, 51, or 53, or other skippable, nonsense, and other mutations. Associations between genotype class and 1-year changes in North Star Ambulatory Assessment total score (ΔNSAA) and in 10-m walk/run velocity (Δ10MWR) were studied in each data source with and without adjustment for baseline prognostic factors. RESULTS: The studied genotype classes accounted for approximately 2% of variation in ΔNSAA outcomes after 12 months, whereas other prognostic factors explained >30% of variation in large data sources. Based on a meta-analysis across all data sources, pooled effect estimates for the studied skip-amenable mutation classes were all small in magnitude (<2 units in ΔNSAA total score in 1-year follow up), smaller than clinically important differences in NSAA, and were precisely estimated with standard errors <1 unit after adjusting for nongenotypic prognostic factors. DISCUSSION: These findings suggest the viability of trial designs incorporating genotypically mixed or unmatched controls for up to 12 months in duration for motor function outcomes, which would ease recruitment challenges and reduce numbers of patients assigned to placebos. Such trial designs, including multigenotype platform trials and hybrid designs, should ensure baseline balance between treatment and control groups for the most important prognostic factors, while accounting for small remaining genotype effects quantified in this study. Lippincott Williams & Wilkins 2023-04-11 /pmc/articles/PMC10103111/ /pubmed/36725339 http://dx.doi.org/10.1212/WNL.0000000000201626 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Research Article Muntoni, Francesco Signorovitch, James Sajeev, Gautam Lane, Henry Jenkins, Madeline Dieye, Ibrahima Ward, Susan J. McDonald, Craig Goemans, Nathalie Niks, Erik H. Wong, Brenda Servais, Laurent Straub, Volker Guglieri, Michela de Groot, Imelda J.M. Chesshyre, Mary Tian, Cuixia Manzur, Adnan Y. Mercuri, Eugenio Aartsma-Rus, Annemieke DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials |
title | DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials |
title_full | DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials |
title_fullStr | DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials |
title_full_unstemmed | DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials |
title_short | DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials |
title_sort | dmd genotypes and motor function in duchenne muscular dystrophy: a multi-institution meta-analysis with implications for clinical trials |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103111/ https://www.ncbi.nlm.nih.gov/pubmed/36725339 http://dx.doi.org/10.1212/WNL.0000000000201626 |
work_keys_str_mv | AT muntonifrancesco dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT signorovitchjames dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT sajeevgautam dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT lanehenry dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT jenkinsmadeline dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT dieyeibrahima dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT wardsusanj dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT mcdonaldcraig dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT goemansnathalie dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT nikserikh dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT wongbrenda dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT servaislaurent dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT straubvolker dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT guglierimichela dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT degrootimeldajm dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT chesshyremary dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT tiancuixia dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT manzuradnany dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT mercurieugenio dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT aartsmarusannemieke dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials AT dmdgenotypesandmotorfunctioninduchennemusculardystrophyamultiinstitutionmetaanalysiswithimplicationsforclinicaltrials |